AU Patent

AU2007275365A1 — RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)

Assigned to Sirna Therapeutics Inc · Expires 2008-01-24 · 18y expired

What this patent protects

Patent listed against inclisiran-sodium.

Drugs covered by this patent

Patent Metadata

Patent number
AU2007275365A1
Jurisdiction
AU
Classification
—
Expires
2008-01-24
Drug substance claim
No
Drug product claim
No
Assignee
Sirna Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.